Orphan drugs for the treatment of aspergillosis: Focus on isavuconazole

Keyphrases

• Activity Data 20%
• Adverse Drug 20%
• Adverse Effects 20%
• Adverse Events 20%
• Alternative Therapy 20%
• Aspergillosis 100%
• Aspergillus Infection 20%
• Aspergillus Species 20%
• Clinical Data 20%
• Clinical Trials 20%
• Drug Interactions 20%
• Emerging Alternatives 20%
• First-line Therapy 20%
• Immunocompromised Patients 20%
• In Vitro Activity 20%
• Invasive Aspergillosis 80%
• Isavuconazole 100%
• Model Trial 20%
• Nonlinear Pharmacokinetics 20%
• Orphan Drugs 100%
• Pharmacokinetic Profile 20%
• Pharmacologic 20%
• Triazole 20%
• Voriconazole 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Aspergillosis 100%
• Aspergillus 20%
• Clinical Trial 20%
• Drug-Drug Interaction 20%
• Immunocompromised Patient 20%
• Invasive Aspergillosis 80%
• Isavuconazole 100%
• Orphan Drug 100%
• Pharmacokinetics 40%
• Triazole 20%
• Voriconazole 40%